文献速递胸部肿瘤

免疫检查点抑制剂联合化疗对比伊匹木单抗联合纳武利尤单抗方案治疗PD-L1 TPS 1-49%的非小细胞肺癌患者的比较:TOPGAN2023-01

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
PubMed 文献 · Eur J Cancer · 2024-11-05

这项多中心回顾性研究纳入401例PD-L1 TPS 1-49%且开始一线化疗的非小细胞肺癌患者,其中308例接受免疫检查点抑制剂联合化疗(ICI-chemo),93例接受伊匹木单抗联合纳武利尤单抗(I-N)为基础的治疗。倾向性评分匹配后,两组总生存(OS)和无进展生存(PFS)无差异(OS:HR 0.83,95%CI 0.54-1.26;PFS:HR 0.72,95%CI 0.52-1.00)。在PD-L1 TPS 25-49%亚组中,ICI-chemo组OS有获益趋势(HR 0.30,95%CI 0.09-0.85)。

要点

  • PD-L1 TPS 1-49%的NSCLC患者中,ICI联合化疗与I-N为基础治疗的OS和PFS无显著差异。
  • 倾向性评分匹配后OS的HR为0.83(95%CI 0.54-1.26),PFS的HR为0.72(95%CI 0.52-1.00)。
  • PD-L1 TPS 25-49%亚组中ICI联合化疗组OS有获益趋势(HR 0.30,95%CI 0.09-0.85)。

核心结论

  • 在PD-L1 TPS 1-49%的NSCLC患者中,ICI联合化疗组与I-N为基础治疗组之间的生存结局无显著差异。
  • 基于亚组分析结果,ICI联合化疗可能对PD-L1 TPS 25-49%的NSCLC治疗更优。

研究设计与样本

  • 多中心回顾性研究,纳入PD-L1 TPS 1-49%且开始一线化疗的NSCLC患者401例,其中308例接受ICI联合化疗,93例接受I-N为基础的治疗。
  • 采用倾向性评分匹配分析调整各种混杂因素并评估治疗疗效。

主要发现

  • ICI联合化疗组中位OS为21.0个月,I-N为基础治疗组中位OS为20.0个月。
  • 倾向性评分匹配后,ICI联合化疗组与I-N为基础治疗组之间OS无差异(HR 0.83,95%CI 0.54-1.26),PFS无差异(HR 0.72,95%CI 0.52-1.00)。
  • 在PD-L1 TPS 25-49%亚组中,ICI联合化疗组OS有获益趋势(HR 0.30,95%CI 0.09-0.85)。
  • 治疗中断在ICI联合化疗组发生于26.2%的患者,在I-N为基础治疗组发生于41.9%的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint inhibitors (ICIs) plus chemotherapy is now a standard treatment for non-small cell lung cancer (NSCLC). Whether ICI plus chemotherapy (ICI-chemo) or ipilimumab plus nivolumab (I-N)-based therapy is superior for patients with NSCLC with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1-49 % has not been evaluated. METHODS: This multicenter retrospective study included NSCLC patients with a TPS score of 1-49 %, who began first-line chemotherapy. Propensity score matching analysis was used to adjust for various confounders and evaluate treatment efficacy. RESULTS: A total of 401 patients were enrolled, of whom 308 received ICI-chemo and 93 received I-N-based therapy. The median OS was 21.0 months in the ICI-chemo group and 20.0 months in the I-N-based therapy group. After propensity score matching, there was no difference in OS or PFS between the ICI-chemo group and the I-N-based therapy group (OS: hazard ratios (HR), 0.83; 95 % confidence interval [CI], 0.54-1.26, PFS: HR, 0.72; 95 % CI, 0.52-1.00). Among PD-L1 TPS 25-49 %, there was a tendency for OS to be favorable for the ICI-chemo group (OS: HR, 0.30; 95 % CI, 0.09-0.85). Treatment discontinuation occurred for 26.2 % of the patients in the ICI-chemo group and 41.9 % in the I-N-based therapy group. CONCLUSIONS: Among PD-L1 TPS 1-49 %, there was no significant difference in survival outcomes between the ICI-chemo group and the I-N-based therapy group. Based on the results of a subgroup analysis, ICI-chemo may be superior for treating NSCLC with a TPS of 25-49 %.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tanaka H, Makiguchi T, Tozuka T, et al. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01. Eur J Cancer. 2024. PMID: 39522333. doi:10.1016/j.ejca.2024.115117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。